ENDO: Distinct Urine Metabolite Profile in Obese Youth With T2DM

This article originally appeared here.
Share this content:
ENDO: Distinct Urine Metabolite Profile in Obese Youth With T2DM
ENDO: Distinct Urine Metabolite Profile in Obese Youth With T2DM

THURSDAY, April 6, 2017 (HealthDay News) -- Obese youth with type 2 diabetes have a distinct metabolomic profile, according to a study presented at the annual meeting of The Endocrine Society, held from April 1 to 4 in Orlando, Fla.

Pinar Gumus Balikcioglu, M.D., from the Duke University Medical Center in Durham, N.C., and colleagues recruited 33 obese African-American children ages 8 to 18 from pediatric obesity and diabetes clinics. Twenty-four hour urine samples were analyzed to identify key urinary metabolic signatures.

The researchers found that among 187 metabolites identified, three metabolites were significantly higher in obese youth with type 2 diabetes than in obese youth without diabetes. The three metabolites related to mitochondrial dysfunction and respiratory chain defects. Compared to those without diabetes, subjects with diabetes had a significantly lower level of one metabolite, 5-hydroxy-indoleacetic acid, the major metabolite of serotonin (P = 0.0007).

"Validation of our findings in larger clinical trials could provide a new noninvasive approach to identification of biomarkers for metabolic risk in both children and adults," Balikcioglu said in a statement. "More importantly, analysis of serotonin metabolism may provide new therapeutic targets for diabetes prevention and treatment."

Abstract
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths